- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in dr reddys lab
Dr Reddy's Net Profit Declines 76% To Rs 88 Cr In Q4
Revenues during the quarter under discussion were up by 15 per cent to Rs 5,436.8 crore compared to Rs 4,728.4 crore in the last quarter of FY21
Read MoreDr Reddy's Re-Launches Naproxen Sodium OTC Tablets In US Market
Dr Reddys Naproxen Sodium Tablets USP, 220 mg, will be available in multiple-pack sizes to allow consumers a variety of purchasing options.
Read MoreDr Reddy's Launches Generic Invanz Injection In US Market
The Invanz brand and generic market had US sales of approximately USD 205 million MAT (moving annual total) for the most recent twelve months ending in March 2021 according to IQVIA Health.
Read MoreDr Reddy's Gets 3 Observations From USFDA For US-Based API Plant
The audit of the company's active pharmaceutical ingredients (API) manufacturing plant at Middleburg, New York has been completed by the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a regulatory filing.
Read MorePfizer Moves US Court Against Aurobindo Pharma, Dr Reddy's On Cancer Drug
The generic companies assert the invalidity and non- infringement of two composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023
Read MoreIndia Approves Avigan (Favipiravir) for COVID-19 Treatment
In India, GRA and Dr. Reddy’s will look to distribute Avigan® through private healthcare providers opting for a premium quality drug. The initial supply will contain the original Avigan®, made in Japan.
Read MoreDr Reddy's Net Profit Falls 13 % To Rs 579 Cr In June Quarter
The revenue went up 15 per cent at Rs 4,418 crore as against Rs 3,844 crore while earnings before interest, taxes, depreciation and amortisation (EBITDA) were up 2.5 per cent at Rs 1,162 crore in Q1 FY21 as compared to Rs 1,134 crore in Q1 FY20.
Read MoreDr Reddy's Completes Acquisition Of Wockhardt's Select Business Divisions
This deal is in line with our strategic focus on India and has paved a path for accelerated growth and leadership in the domestic market,
Read MoreDr Reddy's Fourth-quarter Profit Falls 19% On US Headwinds
Revenue from the generics business in North America, its biggest market, dropped 6 percent to Rs 14.49 billion due to price erosions and increased competition
Read MoreDr Reddy's Acquires 6 OTC Brands From Ducere Of US
Dr Reddy's Laboratories said on Wednesday that it has acquired a range of consumer health or over-the-counter brands from the US-based Ducere Pharma Llc for an undisclosed sum
Read More